Pain Therapeutics’ Remoxy Approval Hinges On REMS; FDA Unsure If Drug Is Abuse-Resistant
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees will discuss whether the proposed REMS can adequately determine abuse of the opioid.
You may also be interested in...
FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda
Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.
FDA Cmte. Will Discuss Standards For Abuse-Deterrant Pain Drugs, With Focus On Embeda
Approvability of Alpharma’s abuse-resistant morphine Embeda will facilitate a broader discussion of approval standards by advisory committees Nov. 14.
A Seat At The Drug Safety Table: Public Citizen’s Wolfe Joins FDA Advisory Committee
Long-time industry critic Sidney Wolfe will serve as permanent member of the Drug Safety and Risk Management panel for the next four years.